Pfizer's Bear Case Is Breaking

Pfizer's non-COVID commercial portfolio is accelerating, with new launches and business development products growing 22% to a nearly $12 billion annualized run rate. Seagen's oncology portfolio expanded 20% while Biohaven's migraine franchise surged 41%, demonstrating strong commercial momentum beyond the COVID business. COVID revenue is expected to decline from $11 billion in 2024 to approximately $5 billion in 2026, increasing reliance on newer growth drivers. Investors should closely monitor whether the 22%, 20%, and 41% growth rates remain intact, as management now treats them as key performance indicators. Regulatory uncertainty, Paxlovid authorization changes, FDA leadership instability, and ongoing LNP patent litigation continue to pose risks to Pfizer's COVID franchise. Investment Thesis Pfizer’s ( PFE ) investment thesis is gradually moving away from its dependency on pandemic-driven revenue to the power of an aggressively growing non-COVID portfolio. Even though the COVID franchise is still shrinking in This article was written by Yiannis Zourmpanos 17.61K Followers Follow Hi, I'm Yiannis. Spotting winners before they break out is what I do best.Experience: Previously worked at Deloitte and KPMG in external/internal auditing and consulting. Education: Chartered Certified Accountant, Fellow Member of ACCA Global, with BSc and MSc degrees from U.K. business schools. Investment Style: Spotting high-potential winners before they break out, focusing on asymmetric opportunities (with at least upside potential of 3-5X outweighing the downside risk). By leveraging market inefficiencies and contrarian insights, we seek to maximize long-term compounding while protecting against capital impairment.Risk management is paramount—we seek a strong margin of safety to protect against capital impairment while maximizing long-term compounding. Our 2-3 year investment horizon allows us to ride out volatility, ensuring that patience, discipline, and intelligent capital allocation drive outsized returns over time. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that do include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.